One platform,
whoever you serve.
Patient-centric infrastructure for microsampling and monitoring: samples collected at home or at the point of care, analysed in accredited laboratories, results matched with continuous data from wearables. We integrate labs and never compete with them.
A neutral platform, not a lab.
Humans Nexus is the infrastructure between the patient and the laboratory (a single platform of regulated collection kits, clinical-grade logistics under documented chain of custody, and software that lands structured results in the lab system). Our partners reach the patient, and we never sell directly (whichever of them wins).
European-owned, MDR/IVDR-native and GDPR-native, the platform routes every matrix (capillary blood, saliva, urine and stool) into accredited laboratories. We are deliberately neutral: we connect labs to remote demand and never compete with the lab that runs the test.
Built for your team.
Five buyers, one platform. The infrastructure is the same; the value lands differently depending on whether you run the test, the trial, the therapy, the app or the risk pool.
Microsampling & monitoring.
Every programme acquires data one of two ways (a discrete sample sent to an accredited lab, or a continuous signal followed over time). Both run on the same platform.
Discrete, patient-collected samples (capillary blood, saliva, urine and stool) returned to an accredited laboratory under documented chain of custody. Explore microsampling →
Continuous physiological signals captured at home and followed over time, the trend alongside the molecule. Explore monitoring →
Regulated kits and clinical-grade logistics, orchestrated on one platform, carry both modes (into the same accredited labs, through the same integration). See the platform →
Neutral on purpose.
A platform only works if every party can trust it. So Humans Nexus does not run a laboratory and does not own results. We integrate ISO 15189-accredited labs and route remote demand to them; per-parameter accreditation stays with the lab that holds it. For partners on every other side (CROs, sponsors, digital-health and insurers) that neutrality is what makes the platform safe to build on.
Kits, logistics, software.
Whatever your segment, you build on the same three layers, one regulated platform from the patient’s home to the accredited lab.
Good to know.
Do you run your own laboratory?
No. Humans Nexus is a neutral, patient-centric platform (it orchestrates regulated kits, clinical-grade logistics, contracted practices and ISO 15189-accredited laboratories). We integrate labs and never compete with them; per-parameter accreditation stays with the lab that runs the test.
Do you sell directly to patients?
No. Our partners (laboratories, CROs, pharma, digital-health companies and insurers) reach the patient. We provide the infrastructure underneath and never sell directly.
Which segment is right for us?
If you run the test, start with clinical laboratories. Running trials, see pharma & CROs. Building a product, see digital health. Carrying risk, see insurers.
What can be collected remotely?
Capillary blood (in liquid, VAMS and dried-blood-spot formats) plus saliva, urine and stool, all orchestrated on one platform. Validated remote use is published across at-home HbA1c, pediatric PK, therapeutic drug monitoring, anti-doping and decentralised trials.
Where do you operate?
Humans Nexus is European-owned and built MDR/IVDR-native and GDPR-native for the European regulatory frame.
Everything people build on the platform.
From decentralised trials to population screening, clinical-grade collection becomes infrastructure that healthcare and life-sciences teams build on (with partners reaching the patient, never us).
- The problem
- Site visits are the largest source of dropout and cost in clinical research. Participants miss appointments, and the data simply never gets collected.
- How Nexus does it
- Validated collection kits ship to participants anywhere in the EU. They collect at home, return the sample under documented chain of custody, and structured results land in the trial system through one API, no site visit required.
- The outcome
- Higher retention, real adherence, and a lower cost per participant (life-sciences-grade data, collected at home).
- The problem
- Optimising a dose needs repeated blood levels, but routine clinic draws are impractical for ongoing, at-home monitoring.
- How Nexus does it
- Patients collect a fixed-volume VAMS sample at home on schedule. Because the volume is precise and hematocrit-independent, the lab returns reliable quantitation by LC-MS/MS.
- The outcome
- Accurate, repeatable drug levels from the patient's home, on the cadence the therapy actually needs.
- The problem
- Screening at scale (newborn, serosurveillance, colorectal) is logistically and financially heavy when every sample needs a clinic and a cold chain.
- How Nexus does it
- Low-cost dried-blood-spot or stool-FIT kits mail at scale and return ambient-stable, with no refrigeration, under full chain of custody.
- The outcome
- Reach and cost-efficiency for population programmes that conventional phlebotomy can't match.
- The problem
- Children fear needles, veins are small, and draws fail, so pediatric tests get postponed and pediatric trials under-recruit. The youngest patients generate the least data.
- How Nexus does it
- A touch-activated upper-arm device (no lancet, and preferred to a needle in a peer-reviewed study, sticker-decorated by the child) applied under healthcare-professional supervision at the practice or point of care, with consent recorded in Flow and full chain of custody to an accredited laboratory.
- The outcome
- Blood tests that actually happen, trials families stay in, and pediatric care that finally sees its patients. The pediatrics story →
The wait is hard enough
without the needles.
- The problem
- A fertility cycle is monitored in blood (estradiol, LH, progesterone, checked every few days) which has meant a dawn clinic queue and a needle in the same tender arm, again and again, at the hardest time.
- How Nexus does it
- A touch-activated upper-arm device the adult patient self-collects at home (no lancet, no supervision, no queue) with identity attested and consent recorded in Flow, and full chain of custody to an accredited laboratory in time for the day’s dosing.
- The outcome
- Monitoring patients don’t dread, fewer phlebotomy slots to staff, and cycles that fit around life. The fertility story →
- The problem
- A telehealth product can consult and prescribe, but it can't collect a clinical sample. The diagnostic step happens off-platform, if at all.
- How Nexus does it
- One API orders kits and ingests structured, clinical-grade results back into the app or EHR. The patient collects at home; the platform never touches a lab.
- The outcome
- Real diagnostics inside a digital-health journey, on a recurring, defensible platform.
- The problem
- Chronic conditions need repeated data, but repeated clinic visits don't happen, so the picture between appointments is blank.
- How Nexus does it
- Scheduled at-home collection across matrices, paired with continuous monitoring signals through Pulse (the trend and the molecule, from the same patient).
- The outcome
- A continuous molecular and physiological picture, captured at home, over months.
Build on the platform.
Tell us your segment and your programme (we&rsquo);ll map the kit, the matrix and the platform to it.